Skip to search formSkip to main contentSkip to account menu

TCV 309

Known as: TCV-309 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Platelet Aggregation InhibitorsPyridinium CompoundsTetrahydroisoquinolines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
Development of tactile allodynia and thermal hyperalgesia by intrathecally administered platelet-activating factor in mice
Highly Cited
2000
Highly Cited
2000
Decreased organ failure in patients with severe SIRS and septic shock treated with the platelet-activating factor antagonist TCV-309: a prospective, multicenter, double-blind, randomized phase II…
Sepsis and organ failure remain the main cause of death on the ICU. Sepsis is characterized by a severe inflammatory response, in… 
1999
1999
Combined treatment with endothelin- and PAF-antagonists reduces posttransplant lung ischemia/reperfusion injury.
1996
1996
TREATMENT WITH THE PLATELET-ACTIVATING FACTOR ANTAGONIST TCV-309 IN PATIENTS WITH SEVERE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: A PROSPECTIVE, MULTI-CENTER, DOUBLEBLIND, RANDOMIZED PHASE II TRIAL;
In a prospective randomized, double-blind, placebo-controlled clinical study, the safety and efficacy of the platelet-activating… 
Highly Cited
1994
Highly Cited
1994
Platelet-activating factor antagonist TCV-309 attenuates the induction of the cytokine network in experimental endotoxemia in chimpanzees.
Platelet-activating factor (PAF) has been postulated to play a role in the pathogenesis of sepsis. Additionally, in vitro studies… 
1993
1993
Effect of the platelet‐activating factor antagonist, TCV‐309, and the cyclo‐oxygenase inhibitor, ibuprofen, on the haemodynamic changes in canine experimental endotoxic shock
1 The present study was conducted in order to examine the effects of the platelet‐activating factor (PAF) antagonist, TCV‐309… 
1993
1993
Effects of a platelet activating factor antagonist on oedema formation following burns.
Highly Cited
1992
Highly Cited
1992
Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Pharmacological profiles of a novel specific platelet activating factor (PAF) antagonist, TCV-309 (3-bromo-5-[N-phenyl-N-[2-[2… 
1992
1992
Pharmacological profile of TCV-309--a potent PAF antagonist.
TCV-309 potently and specifically inhibited the diverse biological actions of PAF such as platelet aggregation, hypotension… 
Highly Cited
1992
Highly Cited
1992
Role of platelet activating factor in pathogenesis of acute pancreatitis in rats.
The importance of platelet activating factor in acute pancreatitis was examined by determining the tissue content of endogenous… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)